Swedish Researchers Develop Enzyme Treatment to Combat Antibiotic Resistance
Researchers at Karolinska Institutet unveil a promising enzyme-based treatment to tackle antibiotic-resistant bacteria.
- • Multiresistant bacteria are on the rise in Sweden and globally.
- • Karolinska Institutet researchers found that endolysin can restore antibiotic effectiveness.
- • Mice infected with resistant bacteria were cured using the new treatment method.
- • Effective treatment is crucial within two days to avoid severe complications.
Key details
Sweden is facing an alarming rise in antibiotic-resistant bacteria, impacting the treatment of diseases such as meningitis and pneumonia. In a significant breakthrough, researchers from Karolinska Institutet have discovered a novel method that could restore the effectiveness of antibiotics against these resistant strains.
A recent study revealed that mice infected with penicillin-resistant pneumococci, which cause conditions like meningitis, were cured after receiving a combination of antibiotics and an enzyme known as endolysin. Endolysin, derived from bacteriophages—viruses that specifically infect bacteria—has shown the ability to combat antibiotic resistance effectively. Federico Iovinos, an associate professor of medical microbiology at the institute, emphasized the critical timing for treatment, stating that affected patients must receive care within a maximum of two days to prevent serious neurological complications or death.
As antibiotic resistance becomes an increasingly pressing issue in Sweden and globally, this advancement offers a glimmer of hope for new treatment routes. Researchers are optimistic about further exploring the application of endolysin against various resistant bacterial types, with aims to potentially apply this method for treating human cases of meningitis in the future. The urgency of action in addressing this public health crisis is palpable, as the efficacy of conventional antibiotics continues to diminish against these stubborn bacterial strains.